PBRM1 and neoplasm: The same investigators demonstrated the enrichment of dendritic cells and a favorable ratio of M1-like macrophages to tumor-promoting M2-like macrophages in PBRM1-deficient tumors, providing additional evidence for the use of immunotherapy targeting the tumor microenvironment.